Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Zealand slides as Boehringer-partnered obesity drug underwhelms
With the readout echoing earlier data that underwhelmed analysts, shares in Boehringer’s partner Zealand Pharma fell 12% in early trading in Denmark.
Nick Paul Taylor
Oct 1, 2026 6:15am
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose
Sep 30, 2026 4:57am
Novo inks $1.3B deal to unlock long-acting obesity injectables
Sep 25, 2026 4:53am
Enveda reaps $311M round to help become ‘household name’
Sep 23, 2026 9:47am
Lilly cans early obesity drug after ‘high bar’ not met
Sep 14, 2026 12:45pm
Corbus posts obesity data in area where Novo, Sanofi stumbled
Sep 14, 2026 10:07am
